Arresting the biosynthesis of Lipid A to hinder Escherichia coli and Pseudomonas aeruginosa through fatty diglyceride.

Lipid A is a fragment of lipopolysaccharide (LPS) in gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa; hence inhibition of its biosynthesis is one of the plausible ways of preventing such bacteria from growth and thus preventing gastrointestinal diseases caused by Escherichia coli and pseudomonas aeruginosa. This research revolves around the development of antibiotic glyceride derivatives for the inhibition of the biosynthesis of lipid A. To target the enzymes involved in the biosynthesis of lipid A, four N,N-dimethylaminobenzoate moiety containing fatty diglyceride derivatives were synthesized through a multi-step synthetic scheme starting from glycerol.

Directly compressed rosuvastatin calcium tablets that offer hydrotropic and micellar solubilization for improved dissolution rate and extent of drug release.

The objective was to use caffeine and Soluplus® to improve the dissolution rate and to maintain a concentration of BCS Class II rosuvastatin calcium that exceeds its solubility. Caffeine and Soluplus® together substantially improved the dissolution rate and the extent of rosuvastatin release. Formulations for direct compression tablets included Formulation F1, a control with drug but with neither caffeine nor Soluplus® present; F2 with drug-caffeine complex; F3 with drug and Soluplus® and F4 with drug-caffeine complex and Soluplus®.